Established Cardiovascular Disease Treatment Algorithm by Line of Therapy

Start with the disease phenotype

“Established cardiovascular disease” often means clinically manifest atherosclerotic cardiovascular disease, or ASCVD. That umbrella can include prior myocardial infarction, acute coronary syndrome, coronary revascularization, chronic coronary disease, atherosclerotic ischemic stroke or transient ischemic attack, and symptomatic peripheral artery disease. These conditions share risk factors, but they do not share one medication algorithm.

A safe treatment review asks:

1. Which vascular territory is affected?
2. Was there a recent acute event, stent, bypass operation, or limb revascularization?
3. Is there atrial fibrillation, a mechanical valve, venous thrombosis, or another reason for anticoagulation?
4. What is the bleeding history?
5. Is left ventricular ejection fraction reduced or is heart failure present?
6. Are diabetes, chronic kidney disease, obesity, hypertension, smoking, or high lipoprotein(a) adding risk?
7. What are the current LDL-C, non-HDL-C, triglycerides, blood pressure, kidney function, and medication tolerability?

This prevents incompatible combinations and false rules. For example, dual antiplatelet therapy may be appropriate after an acute coronary syndrome, while long-term dual antiplatelet therapy is generally not the default after an ischemic stroke. A person with atrial fibrillation may need anticoagulation rather than simply adding more antiplatelet drugs.

A phenotype-based decision map

| Clinical situation | Core evidence-based questions | Common next decision | |---|---|---| | Recent acute coronary syndrome | PCI or medical management? Bleeding risk? Oral anticoagulation? | Choose antiplatelet strategy and duration under the 2025 ACS guideline | | Stable chronic coronary disease | Angina? Prior MI timing? Ejection fraction? | Long-term antiplatelet, lipid lowering, symptom therapy, and selective beta-blocker use | | Prior ischemic stroke or TIA | Atherosclerotic, cardioembolic, small-vessel, or other mechanism? | Match antithrombotic and risk-factor treatment to stroke mechanism | | Symptomatic lower-extremity PAD | Claudication, limb-threatening ischemia, or recent revascularization? | Antiplatelet or dual-pathway therapy, exercise, foot care, and possible revascularization | | ASCVD plus heart failure | Reduced or preserved ejection fraction? Congestion? Kidney function? | Add the heart-failure guideline-directed pathway | | ASCVD plus diabetes or CKD | Albuminuria, eGFR, heart failure, hypoglycemia risk? | Select SGLT2 or GLP-1 therapy for the comorbidity and demonstrated outcome | | ASCVD plus overweight or obesity without diabetes | Does the patient match a cardiovascular-outcome indication? | Consider obesity treatment with proven cardiovascular outcome data |

The map is a review sequence, not a prescription. A medication can appear in several pathways for different reasons.

Lipid lowering is the broadest shared treatment

The 2026 ACC/AHA multisociety dyslipidemia guideline replaces the 2018 cholesterol guideline. It restores explicit LDL-C and non-HDL-C goals, recommends measuring lipoprotein(a) at least once in adulthood, and incorporates ezetimibe, PCSK9 monoclonal antibodies, and bempedoic acid as outcome-based nonstatin options. For ASCVD at very high risk, the LDL-C goal is below 55 mg/dL [1].

Step 1: use a maximally tolerated statin

High-intensity statin therapy is usually the starting point in secondary prevention, unless it is contraindicated or not tolerated. The Cholesterol Treatment Trialists’ meta-analysis found that each 1 mmol/L reduction in LDL cholesterol produced about a one-fifth proportional reduction in major vascular events, with benefit extending across patient groups [2].

“Maximally tolerated” matters. Muscle symptoms require a structured evaluation for timing, interacting drugs, thyroid disease, and alternative statin or dosing strategies. It should not automatically mean abandoning all statins, but a patient should not be forced to repeat a clearly harmful exposure.

Step 2: add treatment when the goal is not reached

Ezetimibe is a common first add-on because it is oral, generic, and has outcome evidence after acute coronary syndrome. If the reduction remains inadequate, a PCSK9 monoclonal antibody can produce a much larger LDL-C decrease. In FOURIER, evolocumab lowered LDL-C and reduced cardiovascular events in patients with ASCVD receiving statin therapy [3].

Bempedoic acid is another outcome-based option, particularly when statin intolerance limits treatment. CLEAR Outcomes enrolled statin-intolerant patients and found fewer major cardiovascular events with bempedoic acid than placebo, while also identifying higher rates of gout and cholelithiasis [4]. Inclisiran lowers LDL-C, but the 2026 guideline notes that cardiovascular-outcome trials are still determining whether that reduction translates into fewer events [1].

The next drug is not chosen by a rigid “line of therapy” alone. Distance from the LDL goal, recent events, cost, injection preference, adverse effects, adherence, and access all matter.

Antithrombotic therapy must match the event

Recent acute coronary syndrome

The 2025 ACC/AHA acute coronary syndrome guideline recommends dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor for at least 12 months after discharge in patients with low bleeding risk. It also provides alternative strategies when bleeding risk is higher and addresses patients who need oral anticoagulation [5].

That does not make 12 months mandatory for every patient. Active bleeding, thrombocytopenia, prior intracranial hemorrhage, frailty, upcoming surgery, stent characteristics, and the need for anticoagulation can change the regimen.

Stable chronic coronary disease

For many patients with chronic coronary disease and no indication for anticoagulation, a single antiplatelet agent is used long term. The 2023 multisociety chronic coronary disease guideline also emphasizes shorter dual-antiplatelet courses for selected patients after PCI and individualized ischemic-versus-bleeding assessment [6].

Ischemic stroke or TIA

Stroke mechanism controls treatment. Noncardioembolic stroke is generally treated with antiplatelet therapy, while atrial-fibrillation-related stroke usually requires anticoagulation. The 2021 AHA/ASA secondary stroke prevention guideline states that long-term aspirin plus clopidogrel is not used for most ischemic stroke patients; short-term dual therapy is reserved for defined situations such as selected minor stroke or high-risk TIA [7].

Peripheral artery disease

The 2024 lower-extremity PAD guideline recommends effective medical therapy, structured exercise, and foot care in addition to antithrombotic and lipid management. For symptomatic PAD and after lower-extremity revascularization, low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin can reduce major cardiovascular and limb events in patients who are not at increased bleeding risk [8].

COMPASS demonstrated fewer cardiovascular events with low-dose rivaroxaban plus aspirin than aspirin alone in stable vascular disease, but major bleeding increased [9]. The combination is therefore a risk-selected option, not a universal add-on.

Beta-blockers and ACE inhibitors are not automatic for everyone

A blanket beta-blocker plus ACE-inhibitor or ARB recommendation for every adult with established CVD is too broad. Current guidance is more specific.

The 2023 chronic coronary disease guideline recommends reevaluating long-term beta-blocker use more than one year after myocardial infarction when there is no left ventricular ejection fraction of 50% or lower, angina, arrhythmia, uncontrolled hypertension, or another indication. It also states that long-term beta-blocker therapy is not recommended to improve outcomes in chronic coronary disease when there has been no MI in the past year, ejection fraction is above 50%, and no other indication exists [6].

Beta-blockers remain important after recent MI in appropriate patients, for angina, selected arrhythmias, and heart failure with reduced ejection fraction. The point is not to stop them abruptly; it is to document the continuing indication.

ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors also have strong roles in heart failure, hypertension, chronic kidney disease with albuminuria, diabetes with selected risk features, and after MI with ventricular dysfunction. They are not interchangeable in every clinical setting and require monitoring of blood pressure, kidney function, and potassium.

Blood pressure and lifestyle treatment

For chronic coronary disease with hypertension, the 2023 guideline recommends a blood pressure target below 130/80 mmHg to reduce cardiovascular events [6]. The path to that target depends on symptoms, orthostatic blood pressure, kidney function, potassium, heart failure, angina, age, and medication interactions. A lower reading is not automatically better if it causes falls, kidney injury, or myocardial ischemia.

Lifestyle care is not a pre-medication waiting period. It continues alongside drug treatment:

• eliminate tobacco exposure with counseling and evidence-based cessation medication;
• use cardiac rehabilitation after eligible myocardial infarction, PCI, CABG, or other qualifying events;
• build aerobic, resistance, and balance activity around symptoms and rehabilitation guidance;
• favor vegetables, fruits, legumes, whole grains, nuts, fish, and unsaturated fats while limiting sodium, refined carbohydrates, and trans fat;
• address sleep apnea, sleep duration, depression, and medication affordability; and
• keep vaccines and routine preventive care current.

Exercise-based cardiac rehabilitation reduces cardiovascular mortality and hospital admission in people with coronary heart disease, although trial populations and program designs vary [10].

Diabetes, kidney disease, heart failure, and obesity pathways

SGLT2 inhibitors

SGLT2 inhibitors are not prescribed merely because ASCVD exists. Their strongest outcome roles depend on type 2 diabetes, heart failure, and chronic kidney disease. In DAPA-HF, dapagliflozin reduced worsening heart failure or cardiovascular death in patients with heart failure and reduced ejection fraction, including those without diabetes [11]. Product choice and eligibility still depend on kidney function, volume status, infection risk, ketoacidosis risk, and the specific indication.

GLP-1 receptor agonists

In SELECT, 17,604 adults age 45 or older with preexisting cardiovascular disease, BMI at least 27 kg/m², and no diabetes were randomized to weekly semaglutide 2.4 mg or placebo. Major cardiovascular events occurred in 6.5% versus 8.0%, respectively, but discontinuation for adverse events was also more common with semaglutide [12].

The result supports semaglutide for people who match the labeled cardiovascular-risk-reduction population. It does not establish that every patient with ASCVD should take a GLP-1 drug or that other GLP-1 products share the same non-diabetes indication.

Heart failure is a separate algorithm

Reduced-ejection-fraction heart failure has its own multi-drug outcome pathway, commonly involving an angiotensin receptor-neprilysin inhibitor or another renin-angiotensin system drug, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. Doses, sequence, and monitoring depend on blood pressure, kidney function, potassium, congestion, and tolerability. A coronary secondary-prevention checklist cannot safely substitute for heart-failure management.

Selected residual-risk therapies

Icosapent ethyl

REDUCE-IT studied statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes plus risk factors. Icosapent ethyl reduced the primary ischemic endpoint, but atrial fibrillation or flutter requiring hospitalization and serious bleeding were numerically or significantly more frequent depending on the outcome definition [13]. This supports a selected high-risk population, not generic fish-oil supplementation.

Low-dose colchicine

COLCOT found fewer ischemic cardiovascular events when low-dose colchicine was started after myocardial infarction [14]. The 2023 chronic coronary disease guideline says colchicine may be considered for secondary prevention in selected patients [6]. Kidney or liver disease, gastrointestinal intolerance, blood disorders, and strong CYP3A4 or P-glycoprotein interactions can make it unsuitable.

Revascularization is symptom- and anatomy-driven

Persistent angina despite medical therapy, left main disease, complex multivessel disease, reduced ventricular function, or limb-threatening ischemia may require revascularization evaluation. A procedure is not simply the “next line” after medications, and medication does not replace urgent revascularization when anatomy or instability demands it.

Monitoring after the plan changes

| Change | What to verify | |---|---| | Start or intensify lipid therapy | Adherence, adverse effects, and repeat lipids at the guideline-appropriate interval | | Change antithrombotic therapy | Exact indication, duration, bleeding, interacting drugs, renal function, and planned procedures | | Add ACE inhibitor, ARB, ARNI, or MRA | Blood pressure, creatinine/eGFR, potassium, and volume status | | Add SGLT2 inhibitor | Kidney function, volume status, genital infection risk, sick-day and perioperative instructions | | Add GLP-1 therapy | Indication, gastrointestinal effects, gallbladder or pancreatitis history, and weight trajectory | | Continue beta-blocker | Current indication, heart rate, blood pressure, fatigue, conduction disease, and taper plan if stopping |

Medication reconciliation should include over-the-counter NSAIDs, decongestants, supplements, and duplicate prescriptions. Those can affect blood pressure, kidney function, bleeding, and adherence.

When symptoms require emergency care

New chest pressure, sudden shortness of breath, fainting, a new facial droop or one-sided weakness, difficulty speaking, a suddenly cold or painful limb, or uncontrolled bleeding requires emergency evaluation. A secondary-prevention appointment or online algorithm is not the right setting for an acute event.

Bottom line

Modern secondary prevention is intensive but individualized. Lipid lowering and lifestyle treatment apply broadly. Antithrombotic therapy depends on vascular territory, event timing, procedures, anticoagulation needs, and bleeding risk. Beta-blockers, ACE inhibitors, SGLT2 inhibitors, GLP-1 drugs, colchicine, icosapent ethyl, and low-dose rivaroxaban each have narrower evidence-based roles.

The highest-quality plan is not the longest medication list. It is the plan in which every treatment has a documented indication, measurable target, monitoring strategy, and stop or review date.